PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics (NASDAQ: PTCT) has approved equity compensation packages for 12 new employees as part of their employment agreements. The inducement grants, approved on April 25, 2025, include:
- 7,000 non-statutory stock options with an exercise price of $49.53 per share (closing price on grant date)
- 10,780 restricted stock units (RSUs)
The stock options have a 10-year term and vest over 4 years, with 25% vesting after the first year and 6.25% quarterly thereafter. RSUs vest annually over 4 years at 25% per year. Both are subject to continued employment. These grants were made under Nasdaq Listing Rule 5635(c)(4) as inducement material to employment.
PTC Therapeutics (NASDAQ: PTCT) ha approvato pacchetti di compensazione azionaria per 12 nuovi dipendenti come parte dei loro contratti di lavoro. Le concessioni di incentivo, approvate il 25 aprile 2025, includono:
- 7.000 opzioni azionarie non statutarie con un prezzo di esercizio di $49,53 per azione (prezzo di chiusura alla data di concessione)
- 10.780 unit脿 di azioni vincolate (RSU)
Le opzioni azionarie hanno una durata di 10 anni e maturano in 4 anni, con il 25% che matura dopo il primo anno e il 6,25% ogni trimestre successivo. Le RSU maturano annualmente in 4 anni al 25% annuo. Entrambe sono soggette alla continuazione del rapporto di lavoro. Queste concessioni sono state effettuate in conformit脿 alla Regola 5635(c)(4) del Nasdaq come incentivo materiale all'impiego.
PTC Therapeutics (NASDAQ: PTCT) ha aprobado paquetes de compensaci贸n en acciones para 12 nuevos empleados como parte de sus acuerdos laborales. Las concesiones de incentivo, aprobadas el 25 de abril de 2025, incluyen:
- 7,000 opciones sobre acciones no estatutarias con un precio de ejercicio de $49.53 por acci贸n (precio de cierre en la fecha de concesi贸n)
- 10,780 unidades restringidas de acciones (RSU)
Las opciones tienen un plazo de 10 a帽os y se consolidan en 4 a帽os, con un 25% consolidado despu茅s del primer a帽o y un 6.25% trimestralmente despu茅s. Las RSU se consolidan anualmente durante 4 a帽os al 25% por a帽o. Ambas est谩n sujetas a la continuidad del empleo. Estas concesiones se realizaron bajo la Regla 5635(c)(4) del Nasdaq como un incentivo material para el empleo.
PTC Therapeutics (NASDAQ: PTCT)電� 12氇呾潣 鞁犾瀰 歆侅洂鞐� 雽�頃� 瓿犾毄 瓿勳暯鞚� 鞚柬櫂鞙茧 欤检嫕 氤挫儊 韺偆歆�毳� 鞀轨澑頄堨姷雼堧嫟. 2025雲� 4鞗� 25鞚� 鞀轨澑霅� 鞙犾澑 氤挫“旮堨棎電� 雼れ潓鞚� 韽暔霅╇媹雼�:
- 7,000臧滌潣 牍勲矔鞝� 欤检嫕 毵れ垬 鞓奠厴 (攵�鞐澕 膦呹皜鞚� 欤茧嫻 $49.53鞚� 頄夓偓臧�瓴�)
- 10,780臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)
欤检嫕 毵れ垬 鞓奠厴鞚� 10雲� 毵岅赴鞚措┌ 4雲勳棎 瓯胳硱 氩犾姢韺呺悩氅�, 觳� 頃挫棎 25%臧� 氩犾姢韺呺悩瓿� 鞚错泟 攵勱赴氤勲 6.25%鞌� 氩犾姢韺呺惄雼堧嫟. RSU電� 4雲勳棎 瓯胳硱 毵る厔 25%鞌� 氩犾姢韺呺惄雼堧嫟. 霊� 氤挫儊 氇憪 瓿勳啀 瓿犾毄 靸來儨鞐� 霐半澕 鞝侅毄霅╇媹雼�. 鞚� 氤挫“旮堨潃 瓿犾毄 鞙犾澑 氇╈爜鞙茧 雮橃姢雼� 靸侅灔 攴滌箼 5635(c)(4)鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.
PTC Therapeutics (NASDAQ : PTCT) a approuv茅 des packages de r茅mun茅ration en actions pour 12 nouveaux employ茅s dans le cadre de leurs contrats de travail. Les attributions d鈥檌ncitation, approuv茅es le 25 avril 2025, comprennent :
- 7 000 options d鈥檃chat d鈥檃ctions non statutaires avec un prix d鈥檈xercice de 49,53 $ par action (cours de cl么ture 脿 la date d鈥檃ttribution)
- 10 780 unit茅s d鈥檃ctions restreintes (RSU)
Les options d鈥檃chat ont une dur茅e de 10 ans et sont acquises sur 4 ans, avec 25 % acquis apr猫s la premi猫re ann茅e puis 6,25 % chaque trimestre. Les RSU sont acquises annuellement sur 4 ans 脿 raison de 25 % par an. Les deux sont conditionn茅es 脿 la poursuite de l鈥檈mploi. Ces attributions ont 茅t茅 effectu茅es conform茅ment 脿 la r猫gle 5635(c)(4) du Nasdaq en tant qu鈥檌ncitation li茅e 脿 l鈥檈mploi.
PTC Therapeutics (NASDAQ: PTCT) hat Aktienverg眉tungspakete f眉r 12 neue Mitarbeiter im Rahmen ihrer Arbeitsvertr盲ge genehmigt. Die am 25. April 2025 genehmigten Anreizzuteilungen umfassen:
- 7.000 nichtstatutarische Aktienoptionen mit einem Aus眉bungspreis von 49,53 USD pro Aktie (Schlusskurs am Gew盲hrungstag)
- 10.780 Restricted Stock Units (RSUs)
Die Aktienoptionen haben eine Laufzeit von 10 Jahren und werden 眉ber 4 Jahre vestet, wobei 25 % nach dem ersten Jahr und danach viertelj盲hrlich 6,25 % vesten. RSUs vesten j盲hrlich 眉ber 4 Jahre mit 25 % pro Jahr. Beide sind an eine fortgesetzte Besch盲ftigung gebunden. Diese Zuteilungen erfolgten gem盲脽 der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz im Zusammenhang mit der Besch盲ftigung.
- None.
- None.
The inducement grants were approved by PTC's Compensation Committee on April聽25, 2025, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
All stock option awards have an exercise price of聽
ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to innovate new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. To learn more about PTC, please visit us at 聽and follow us on Facebook, X, and LinkedIn.
For more information please contact:
Investors:
Ellen Cavaleri
+1 (615) 618-8228
[email protected]
Media:
Jeanine Clemente
+1 (908) 912-9406
[email protected]
View original content to download multimedia:
SOURCE PTC Therapeutics, Inc.
FAQ
What equity compensation did PTC Therapeutics (PTCT) grant to new employees in April 2025?
What is the vesting schedule for PTCT's April 2025 stock option grants?
How do the RSUs vest in PTC Therapeutics' April 2025 inducement grants?
What is the exercise price of PTCT's April 2025 inducement stock options?
